Nutraceutical helps patient see clearly

Article

Longevinex (Resveratrol), a nutraceutical matrix, can remove lipofuscin deposits from the retina to improve visual acuity and night vision, according to research presented at this year's meeting of the American Academy of Optometry in Seattle, US.

Longevinex (Resveratrol), a nutraceutical matrix, can remove lipofuscin deposits from the retina to improve visual acuity and night vision, according to research presented at this year's meeting of the American Academy of Optometry in Seattle, US.

Stuart Richer, OD, PhD, FAAO, Chief of the Optometry Section at the Veterans Medical Center in North Chicago, US and colleagues treated a male patient (aged 80 years) with nutraceuticals to improve his night vision. No improvement was observed. After five months of treatment with the Longevinex supplement, which removes excess minerals (including calcium, iron and copper) through chelation, the subject showed a statistically significant increase in night vision, visual acuity, side vision and colour perception.

Although Dr Richer concedes that Longevinex is not yet ready to be marketed as a treatment, the results so far have been positive and there have been no side effects.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.